Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Oct 2024

Abstract excerpt

The global aging population is leading to an increasing incidence of cancer, exacerbating the global burden of cancer. By 2040, the total number of cancer patients worldwide is projected to reach 28 million. With advancements in tumor molecular biology research and the widespread application of next-generation sequencing technology, precision treatment for cancer has made significant progress in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Oximes
Share to Consensus
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Precision Medicine

Share to Sulfonamides

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 39414592
DOI: 10.3760/cma.j.cn112152-20240409-00142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].PMID 39414592Read ↗

Defining and Targeting BRAF Mutations in Solid Tumors.Semantic proximity Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.Semantic proximity Read ↗

[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].Semantic proximity Read ↗

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read ↗

[BRAF-Mutant Solid Tumor].Semantic proximity Read ↗

Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

Targeting Oncogenic BRAF: Past, Present, and FutureSemantic proximity Read ↗

Targeting the multifaceted BRAF in cancer: New directions.Semantic proximity Read ↗

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read ↗

[Progress of BRAF Gene Alteration in Non-small Cell Lung Cancer].Semantic proximity Read ↗

BRAF Mutations: Oncogenic Drivers in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.